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[CH]Chapter 5 
Homo Adipatus – A New Species: Weight Management, Treatment and Prevention 
Iain Broom and Catherine Rolland 
 
The current obesity epidemic, indeed pandemic, is a major public health problem 
affecting not only the developed nations but also developing countries as they become 
modern industrialised nations. Over the last thirty years the prevalence of obesity has 
increased from 6-8 per cent to almost 25 per cent in the UK [1]. There have always 
been obese individuals within populations over the centuries and indeed in the 
nineteenth century in the UK, increasing abdominal girth was seen as a sign of 
affluence and certainly not frowned upon. Obesity is still seen as such in developing 
countries.  
 
The earliest depiction of the obese phenotype is from stone-age sculptures. The 
existence of such sculptures clearly demonstrates both the social importance attached 
to such a phenotype and the survival advantage conferred in accumulating large fat 
stores. The ‘Venus of Willendorf’ is the most famous of these (http: 
//en.wikipedia.org/wiki/venus_of_Willendorf) whose abundance of body fat is 
suggested to have been diet related (high fat) in association with a sedentary lifestyle 
of cave-confinement during the glacial era. 
 
This is not too far distant from our current dietary consumption of convenience high 
fat, high sugar meals in association with our computer/software driven lifestyle. One 
might suggest that by looking at the changing body shape over the last half century, 
Homo sapiens has evolved into Homo Adipatus (Figure 5.1) and a new species has 
been created. Species development however depends on genetic change and takes 
hundreds if not thousands of years. The obese phenotype has evolved over the last 
fifty years and now accounts for approximately 25 per cent of the UK population and 
30 per cent of the population of the USA.  
 
 
 
The dangers in the rising weight of the nation relate to the impact of obesity on health. 
Obesity impacts extensively on both morbidity and mortality statistics. Although in 
earlier times obesity was seen to have a survival advantage during periods of famine, 
it was also recognised as early as 400 BC by Hippocrates to have concomitant health 
hazards: ‘Sudden death is more common in those who are naturally fat than in the 
lean’; ‘Corpulence is not only a disease in its own right but a harbinger of others’ 
(Hippocrates 400 BC). 
 
Homo Sapiens Homo Adipatus 
    6 million years      50 years 
Figure 5.1 Homo Adipatus: a new species?  
Today obesity is seen as the major aetiological factor in the development of Type 2 
Diabetes Mellitus and is second only to smoking as the primary cause of cancer. 
Obesity is an independent risk for cardiovascular disease and is associated with the 
development of hypertension and dyslipidaemia thus adversely influencing 
cardiometabolic risk. In addition obesity is linked to musculo-skeletal pathology, 
mental health problems and increased risk of inflammatory/infectious disease. 
 
[A]Aetiology of Obesity 
Although there is a clear genetic tendency for obesity to occur in families this in no 
way explains the current explosion of obesity seen across the world in the last half 
century.  It is thought, however, that 40 per cent of the causation of obesity can be 
attributed to genetics. There are a number of single gene defects that can give rise to 
the obese phenotype, e.g. leptin deficiency, MC-4 receptor defects and Laurence, 
Moon-Biedle syndrome. The number of patients with such problems are very few and 
single gene defects do not contribute to the current pandemic.  Obesity tends to be a 
polygenic disorder in origin and the obese phenotype is closely linked to 
environmental interactions with our genetic inheritance. There are numerous factors 
involved in the evolution of the obese  phenotype and these are outlined in Figure 5.2. 
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Figure 5.2 Factors involved in the creation of Homo Adipatus [2] 
 
 The factors influencing the development of the obese phenotype that have changed 
are a) environmental and b) cultural and socio-economic. It is the rapid change in 
these two areas that has impacted on our genetic inheritance to produce the obesity 
epidemic. Indeed obesity is probably the best example of a disease produced by 
altered gene-environment interactions. We have an inherited gene pool, moulded by 
famine over the millennia, that is ill-equipped to handle the current toxic 
obesogenic/diabetogenic environment. The environmental and cultural/socio-
economic changes that have occurred in the last fifty years are huge, and Homo 
sapiens has not been able to adapt to such changes to allow energy homeostasis. Both 
the macro- and micro-environments of population and family have seen tremendous 
changes over this time period. Society operates completely differently in 2007 than in 
1957. There have been major changes in demographics, alterations in transport, major 
increases in automation and differences in the way society perceives risk. All of these 
impact adversely on energy expenditure. Energy intake has also altered dramatically 
both in the nature of the food eaten but also in the mode of preparation and delivery. 
The impact of these changes is to affect a net positive energy balance in the individual 
with consequent deposition of fat and increasing weight.  
 
Table 5.1 outlines the changes in adult energy expenditure in daily living between the 
1950s and 2000s.  
 
Table 5.1 Calorie usage changes over 50 years 
 
In 1980 there were 5000 food items on supermarket shelves whereas in 2000 there 
were 35000 food items. The increase in numbers relates, in the main, to pre-prepared 
and fast foods often energy dense and appetite stimulating. Meals taken out of the 
home and snacking have increased dramatically over the years. All of these factors 
lead to a tendency to increased energy intake. Even the way food is eaten at home has 
changed or rather the environment in which food is eaten has changed. No longer do 
families tend to sit round the table as a group to eat and to have social intercourse. 
This in its own right leads to increased rate of eating and hence increased 
consumption but also tends to reduce energy expenditure on a daily basis by reducing 
small hand and face movements occurring during conversation. Societal changes in 
the shape of the ‘free market economy’, developed effectively in the 1980s, also 
impact on the level of obesity.  
 
 
Table I: Calorie Usage Changes Over 50 Years 
 
Per week 1900s 2000s 
Shopping On foot 2400 By car & 
supermarket 
275 
Washing clothes By hand 1500 Washing machine 270 
Making a coal fire 1300 Lighting a gas fire 3 
Per hour 1990s 2000s 
Lawn mower Manual 500 Electric mower 180 
No power steering 96 With power steering 75 
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Figure 5.4: Effects of free-market economy on national obesity rates  
Figure 5.4 Effects of free-market economy on national obesity rates (Scottish 
Executive, 2006 – see reference at end of document) 
 
The countries, such as the USA, UK and Australia, which have freed up their 
economies most, have the worst obesity prevalence rates. Other countries with some 
degree of economic protection, e.g. Scandinavia, France and Holland have not seen 
acceleration in their obesity prevalence rates in the same way. These external effects 
impact on a control mechanism for energy homeostasis that is molecular in nature and 
designed to cope with frequent episodes of famine and not with our current developed 
world’s plenty. 
 
[A]Control of Energy Metabolism 
The human body is designed to put weight on in periods of plentiful supply of food 
and to use these fat stores in periods of famine. Control mechanisms have evolved to 
allow survival of the species and hence to limit weight loss. Such processes are 
molecular in origin and involve cross-talk between the brain and the gut, and the brain 
and adipose tissue. These molecular mechanisms are extremely complex and are only 
just beginning to be unravelled. As the focus of these mechanisms is on preventing 
weight loss, it explains in part why achieving and maintaining weight loss in the 
overweight and obese is so difficult. The hypothalamus in the brain is the area 
organising the control of energy metabolism. This area could effectively be termed 
the body’s thermostat. This area receives and transmits messages from both the gut 
and adipose tissue and is responsible for responding in particular to energy deficits. A 
large number of protein molecules are involved in these mechanisms, both as 
receptors within the hypothalamus but also proteins/peptides derived from both gut 
and adipose tissue. In brief, appetite signals and the need to eat to maintain body 
weight tend to derive from adipose tissue stores, whereas satiety signals are more 
relevant to gut-brain cross-talk The relationships between these molecules and their 
complex the cross-talk cannot be dealt with here in detail.  
The major nutrients themselves have an effect on both appetite and satiety as does the 
rate of food intake. Protein is the most satiating of the macronutrients, followed by 
carbohydrate whereas fat in the diet has little effect on satiety or appetite. Hence a diet 
high in fat is likely to cause both increased food and energy intake. 
(Discussions with respect to changing macronutrient content of the diet will be dealt 
with below in the treatment section.) 
 
During periods of weight loss the hypothalamus swings into action to try and reduce 
the rate of weight loss by various mechanisms: 
1) Switches from carbohydrate to fat as main energy source 
2) Reduces the need to break down lean body mass to provide carbohydrate 
precursors for energy transduction  
3) Reduces resting energy expenditure  
4) Maintains ‘thermostat’ setting at the original body weight and correlates 
weight to adipose tissue stores. 
5)  The overall effect is to limit weight loss and drive weight gain. Thus, during 
periods of weight loss, the hypothalamus is striving, by molecular means, to 
drive weight regain. Indeed even if weight loss ceases, this part of the brain 
will continue to drive weight upwards unless weight is maintained at the new 
reduced level for some considerable period of time (Figure 5.5).  
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Figure 5.5  Weight loss and maintenance including the influence of hypothalamic 
control. 
Unless the reduced weight loss is maintained constant for some time the 
hypothalamus (thermostat) will not reset at the new lower level, and the tendency is 
for weight regain and indeed overshoot with eventual weight gain from baseline 
weight. This to some extent explains the natural history of obesity, i.e. to gain weight 
of approximately 1 to 2 Kg per year despite intervening weight loss. It is now realised 
that adipose tissue is not just a storage depot for fat but is an endocrine organ in its 
own right producing signal molecules for controlling not only energy metabolism but 
also immune functions, reproductive activity and if allowed to accumulate in ectopic 
areas will increase risk of cardiometabolic disease. If accumulation of fat is increased, 
especially in ectopic areas, this produces a pro-inflammatory state leading to 
exacerbation in inflammatory disease such as asthma and the arthritides but also, by 
altering the redox potential of cells, fat accumulation has a pro-carcinogenic effect 
leading to increased risk of neoplasia. Obesity, after cigarette smoking, is the second 
commonest cause of cancer. Some of the protein signals produced by adipose tissue 
are outlined in Figure 5.6. 
Figure 5.6 Adipose tissue as an endocrine organ  
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It is important to note that ectopic fat such as viscera-associated fat tends to produce 
more metabolically disadvantageous molecules, e.g. pro-inflammatory mediators. In 
addition such ectopic fat deposition tends to lead to reduction in adiponectin secretion 
resulting in increased insulin resistance and increased CVD risk. Increased adipose 
tissue stores also tend to alter levels of sex steroid metabolism leading to both fertility 
problems in females and males and increased risk of ovarian/breast/uterine cancer in 
females and prostate cancer in males. Overall the complexity and understanding of 
control mechanisms in the obese state remain far from clear and further research in 
this area remains a major focus. This is also a clear focus for future drug treatment in 
this area with all major pharmaceutical firms supporting extensive research on energy 
regulation. This does not imply that drug treatment will be a panacea to deal with the 
current obesity pandemic, but it may aid in its control. 
 
[A]Treatment Strategies 
Since the main focus of metabolic control is to prevent weight loss, treatment 
strategies for obesity management have proved extremely difficult for successive 
governments both in the UK and elsewhere. The strategies currently in vogue are 
outlined in Table 5.2. 
Table 5.2 Treatment strategies for the management of overweight and obesity 
Table 5.2: Treatment Strategies for the Management of 
Overweight and Obesity 
 
A. Governmental  
1. Lifestyle Modification 
• Dietary interventions    
• Increased activity    Population and 
• Decreased inactivity    Individual 
• Behaviour modification     
• Stress management     
 
2. Drug Therapy 
 
3. Surgical Intervention 
 
4. Public Health/Health Promotion (to date ineffective) 
 
B. Non-Governmental 
Patient driven interventions with no evidence base 
• Herbal remedies 
• FAD diets 
 
 
Lifestyle alteration remains the main focus of attention in managing the obesity 
epidemic. This effectively concentrates on three areas of intervention with all the 
evidence suggesting that a combined approach using all three aspects is most 
effective. These include: dietary manipulation, increased activity/decreased inactivity 
and behaviour modification. It is clear from the literature that a combination of these 
approaches produces the best results in both the short and long term [3]. Education 
however of both patients and healthcare workers remains the prerequisite for 
successful management, as highlighted in the Counterweight Programme [4,5,6,7]. It 
is important to differentiate between population strategies and individual treatment 
programmes for the successful management of obesity, especially in the areas of diet 
and behaviour change, less so in the advocacy of increased activity. In relation to 
activity levels, it is essential that the population as a whole is encouraged to increase 
their activity levels and oppose their sedentary lifestyle encouraged by the ongoing 
environmental changes linked to automation and the sociopathic computer era. 
Individual increases in activity levels relating to reducing the obese state may have to 
be more tailored to specific individuals. It is not clear what particular form of 
increased activity is suited to a particular patient. Individual preferences may have to 
be taken into consideration. The countryside, open spaces and walking are free to all 
and reliance on ‘exercise on prescription’ is not the panacea. Motivational 
interviewing in this area, encouraging outdoor activities such as simple walking will 
be much more effective and have no cost implications to the patient or government, 
local or national.  
 
Dietary manipulation remains the mainstay of all obesity management programmes. 
As a population the focus on reducing fats and sugar in the diet is appropriate and 
should be maintained. There is considerable evidence in support of high fat, relatively low-
carbohydrate (but high sugar), low fibre diets of Western societies being a major aetiological 
factor in susceptible individuals.  Excess dietary fat is more easily converted to adipose tissue 
lipid stores than carbohydrate (Flatt, 1985); diet-induced thermogenesis is less with fat than 
carbohydrates or protein thus inducing lower metabolic rates with high fat diets (Lean and 
James, 1988; Lean et al., 1989);  and dietary fat has minimal effects on both appetite and 
satiety (Caterson and Broom, 2001). Further education of both patients and healthcare 
staff in this area remains a priority [8]. Fast food outlets, although tending to change 
their attitudes, remain a major barrier in this area, especially in relation to portion 
size.  Thus high fat diets lead to increased overall food consumption with marked 
energy intake thus fuelling the obesity pandemic. 
 
Focusing on a high carbohydrate/low fat diet  is a sensible option for Government to 
adopt as far as population targets are concerned. On an individual basis however, this 
may not be the correct approach. It is essential when dealing with individual obese 
patients, to ascertain their habitual dietary intake. High carbohydrate, low fat intakes 
can also lead to obesity and individual advice may vary from that aimed at 
populations. Indeed the heaviest patients often have a problem with control of 
carbohydrate intake rather than fat. There is therefore room to consider the position of 
low carbohydrate diets in the management of these individuals and taking an 
appropriate diet history is extremely important.  
 The role of very low calorie diets (VLCDs) also needs to be reviewed. In some 
patients this may be important in achieving and maintaining weight loss. In the early 
1970s and 1980s, such diets received much adverse publicity due to their 
inappropriate constitution and consequent association with sudden death. Such 
problems arose out of inappropriate vitamin and trace metal content resulting in 
cardiac dysrhythmias and death. Newer VLCDs do not have such problems and can 
be used safely in appropriate individuals. Commercial meal replacement programmes 
are also appropriate in the management of obesity at least in the short term 
(Ditschuneit, 2006; Truby et al, 2006). More evidence is accumulating for their 
efficacy although major clinical trials are sadly lacking.  
 
Low glycaemic index diets are also in vogue and certainly are associated with a 
reduced insulin response compared with that seen with high glycaemic index diets. 
The reduced insulin response and the flatter blood glycaemic curve seen after food 
intake reduce the post-prandial appetite stimulation seen with carbohydrates that 
produce rapid glycaemic responses. Again major clinical trials in this area are also 
lacking. The theoretical nature of this response is, however, appealing.  
 
Behaviour therapy and associated stress management are also important in achieving 
long-term weight management. Cognitive behaviour therapy is the mainstay of 
behaviour change in association with motivational interviewing. It is also important to 
be aware of the patient’s ‘readiness to change’ before approaching behaviour 
alteration to achieve weight reduction.  
 
Drug therapy is an important adjunct to lifestyle change in the management of 
obesity. It must however not be used in isolation but always in combination with the 
above lifestyle measures. Currently only three drugs are in use and recommended in 
Europe: 
Orlistat – a lipase inhibitor 
Sibutramine – a satiety enhancer 
Rimonabant – an appetite suppressant. 
 
All of these drugs in their clinical trials produced similar amounts of weight loss over 
their two-year period of trial, i.e. 5–10 per cent weight loss, and were superior to 
lifestyle modification alone.  
 
Orlistat effects a net negative energy balance by inhibiting fat digestion and 
absorption in the gut. Approximately 30 per cent of the fat ingested is not absorbed 
and hence appears in the faeces. This drug thus acts as an antabuse to fat in the diet 
and ensures patients maintain a reduced fat intake. Failure to do so produces major 
gastro-intestinal side effects that will not be tolerated by patients or their relatives and 
friends. Excess fat arriving in the large bowel is neutralised by gut bacteria producing 
foul-smelling and colonic irritating molecules resulting in explosive diarrhoea and 
excess flatus. This drug is therefore a useful adjunct where fat in the diet is the main 
contributor to obesity in that patient. If patients do not have a high fat intake and 
excess carbohydrate is the main contributing factor to the obese state, Orlistat will be 
ineffective. Orlistat itself is not absorbed from the gut and is removed in the faeces. 
There are therefore no long-term or systemic effects associated with the drug. Both 
Sibutramine and Rimonabant act centrally on the brain in different areas of the 
hypothalamus. Sibutramine is a satiety enhancer through its mechanism as a serotonin 
reuptake antagoniser. Serotonin is known to be involved in producing satiety signals 
in the hypothalamus. Sibutramine also acts peripherally as a noradrenaline reuptake 
inhibitor and can therefore by increasing heart rate lead to small increases in energy 
expenditure. There is also a risk of increasing blood pressure with this drug and 
careful monitoring is therefore necessary. Because of the effects on the sympathetic 
nervous system its use is contraindicated in patients with cardiovascular disease. As a 
result of possible drug interaction it is also contraindicated in patients receiving anti-
depressant therapy. 
 
Rimonabant acts centrally in the hypothalamus by blocking the endocannabinoid 
pathway. The endocannabinoid system, when stimulated, increases appetite, and is 
known to have increased activity in the obese. Rimonabant blocks the cannabinoid-1 
receptor (CB1) in the hypothalamus thus reducing appetite.  
 
CB1 receptors are also present in other tissues, e.g. gut, adipose tissue, etc. By 
reducing the endocannabinoid tone peripherally rimonabant also has a beneficial 
effect on insulin resistivity and serum cholesterol levels and is thus useful in patients 
with metabolic syndrome or Type 2 diabetes mellitus. Again because of its central 
action, especially in blocking ‘pleasure pathways’ it can markedly adversely affect 
mood. It is therefore not recommended for use in patients with a history of mood 
disorder. The use of drug therapy is restricted to patients with BMI greater than 30 
Kg/m2 or patients with BMI greater than 28 Kg/m2 and with one or more associated 
comorbidities. 
 
Surgery for obesity, bariatric surgery, has gained greater prominence over the years, 
as the obesity epidemic spreads. The development of minimally invasive techniques 
has also added to the increase in use of this approach to manage severe obesity. 
Indeed the primary treatment for patients with a BMI greater than 50 Kg/m2 is now 
that of bariatric surgery as indicated in NICE [9] guidelines for the management of 
obesity. 
 
Bariatric surgery has two main approaches: 
1 A restrictive procedure 
2 A restrictive plus malabsorptive procedure. 
 
Restrictive procedures reduce the capability of the individual to take large amounts of 
food by physically reducing the size of the stomach. This can be achieved by one of 
two methods: laparoscopic banding (Figure 5.7) or a vertical banded gastroplasty . 
Figure 5.7 Restrictive surgical procedure for managing obesity 
 
Both methods create a small gastric pouch with a narrow opening that restricts the 
emptying of solid food but allows normal emptying of liquids. Patients thus feel full 
after a relatively small meal and energy intake is thus drastically reduced. Both 
restrictive methods produce similar degrees of weight loss (~ 30 per cent of body 
weight in two years). Because of the lower complication rate associated with 
laparoscopic banding this has become the restrictive procedure of choice. This 
procedure involves the placement of an encircling inflatable band around the upper 
part of the stomach producing a small (15 ml) gastric pouch. Post-operatively the 
band is progressively tightened, by introducing small volumes of fluid via an injection 
port inserted subcutaneously, until the appropriate degree of restriction is achieved to 
allow suitable weight loss. Such procedures are used in patients where the BMI is >35 
Kg/m2  with co-morbidities or where BMI is > 40 Kg/m2 without co-morbidities.  
 In patients where BMI is > 50 Kg/m2 restrictive/malabsorbtive procedures are more 
often employed. Again a small gastric pouch is created but in addition a varying 
degree of small intestinal bypass is produced thus creating a malabsorptive process. 
The degree of bypass induced by surgery is somewhat dependent on the patient’s 
BMI. A number of different types of malabsorptive procedures are used; the most 
widely performed being the Roux en Y gastric bypass (Figure 5.8). 
  
Food entering the gastric pouch exits through a limb of small bowel joined side to 
side to the pouch. The remainder of the stomach and first part of the intestine is 
bypassed reducing absorptive capacity. There are other means of producing 
malabsorption of food using different surgical techniques, e.g. the biliopancreatic 
diversion and the duodenal switch, although these are not as commonly used as the 
Roux en Y procedure. Other treatments for the management of obesity include 
various herbal remedies and poorly constructed ‘fad’ diets. Neither of these have any 
evidence base on which to substantiate their claims. They are however frequently 
employed by the obese patient in an attempt to achieve and maintain weight loss. A 
great deal of commercial activity surrounds these claims with resultant considerable 
but ineffective expense by the patients. 
 
Figure 5.8 Roux en Y gastric bypass 
 
  
[A]Conclusion 
Despite numerous statements by government and strategic attempts to achieve control 
of the population’s weight, the obesity epidemic marches on. Because of the complex 
nature of the obesity epidemic, there is no easy solution to the problem. Environment 
changes and alterations in socio-economic factors will continue to impact on our 
genetic inheritance and homo sapiens will need to learn to adapt to these changes if 
homo adipatus is to be avoided. This will require major fundamental input from all 
aspects of government and not just the Department of Health. Failure to halt the 
obesity epidemic, especially as it is now affecting our children, will see a return of 
children dying before their parents, a situation not uncommon in the nineteenth 
century and before, but rare in the latter part of the twentieth century. Much greater 
cooperation from the food industry, than hitherto has been seen, is required, as well as 
the cooperation of society as a whole, if the obesity epidemic is to be stopped and 
reversed. 
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